Clinical trials with NeuroEPO progressing in Holguin

The clinical trial with NeuroEPO or Neural CIM in patients with Alzheimer’s disease is progressing in the Cuban province of Holguin, as part of the programs to improve the treatments for this neurocognitive disease.

NeuroEPO, Alzheimer’s disease

According to experts, Alzheimer’s is the most common form of dementia that exists. Image taken from Prensa Latina

Dr. Zaimar Rodríguez Feria, head of the Provincial Group of Clinical Trial, said that this process is currently in a stage of evaluation and inclusion in the territory, where there is a significant number of patients with mild and moderate diagnosis of this pathology.

She emphasized that a multidisciplinary team made up of neurologists, neuropsychologists and psychiatrists, among other specialties, will participate in the study and the leading entities will be the Center of Mental Hygiene, the Provincial Group of Clinical Trial and the Center of Molecular Immunology in the country.

She also pointed out that the evaluation consultations will be held at the Mental Hygiene Center in the city of Holguín and the clinical site of the Lucía Íñiguez Landín Hospital, in order to determine the safety and reliability of this medicine, as well as the evaluation and laboratory analysis of the patients.

She also explained that patients with decompensated basic diseases or under treatment protocols used in cognitive deterioration pathologies will not be considered for inclusion.

The expert referred that this is a multicenter and adaptive phase IV trial, in which more than 1,400 people from all over Cuba will participate, with a 104-week period and foresees a diagnostic test in week 52 and another in week 78.

Employment of the NeuroEPO in patients with Ataxia Espinocerebelosa type II

In Holguín, the study with NeuroEPO in people with Spinocerebellar Ataxia type II has begun, with 46 patients included so far, which will contribute to improve the treatment protocols for this condition, after the EC is concluded, said Rodríguez Feria.

Alzheimer’s is a brain disorder that worsens over time and is characterized by the death of neurons, which causes a gradual deterioration of memory, thinking, behavior and social skills; approximately 55 million people will be diagnosed in the next five years.

With information from ACN – Translated by Radio Angulo